Bendamustim umjesto karmustina pri kondicioniranju kod autologne transplantacije krvotvornih matičnih stanica - usporedba toksičnosti i infektivnih komplikacija

Scientific paper - Case study

• Title (english): Use of bendamustin instead of carmustin in autologous stem cell transplantation conditioning – toxicity and infectious complications comparison
• Author: Ivan Zekanović
• Author: Nadira Duraković
• Author: Martina Morić Perić
• Author: Sandra Bašić-Kinda
• Author: Dubravka Sertić
• Author: Ranka Serventi Seiwerth
• Author: Silva Zupaničić-Šalek
• Author: Pavle Rončević
• Author: Ivo Radman
• Author: Marijo Vodanović
• Author: Alen Ostojić
• Author: Goran Rinčić
• Author: Ines Bojanić
• Author: Vlatka Periša
• Author: Dominik Lozić
• Author: Vedrana Gačić
• Author: Ivana Budisavljević
• Author: Igor Aurer
• Author's institution: University of Zagreb; School of Medicine
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences

Abstract (english)

Inadequate supply of „old and less interesting“ chemotherapeutic agents is becoming a global issue in hemato-
oncology today. In 2016 we were faced with occasional carmustin shortage, one of the most commonly used in
autologous transplant conditioning regimens for lymphoma in our centre, so we decided to use bendamustin instead. We
performed a retrospective analysis of 41 patients treated at our centre who had received bendamustin within BeEA M
protocol and compared them with 40 patients who had received carmustin within BEA M protocol. Both protocols were
used as conditioning protocols before autologous stem cell transplantation. Neutrophil recovery median following
transplantation (AN C>0,5x109/l) was 11 days in the bendamustin group in comparison to 10 days in the carmustin
group.Platelets recovery median following transplantation (PLT >20x109/l) was longer in the bendamustin group (16
vs.13 days) as was blood transfusion dependency (7 vs. 5 days). Infectious complications were not more frequent after
bendamustin, but grade II–III mucositis was more frequent in patients who received carmustin (35% vs.12%). Following bendamustin we had one reported case of nephrotoxicity and cardiac toxicity, not reported with carmustin. Bendamustin
has shown similar hematologic toxicity compared to carmustin but a longer platelet recovery period and a
lower mucositis incidence.

Abstract (croatian)

Unatrag nekoliko godina u hematologiji i onkologiji globalno sve češći problem postaje prikladna opskrba
„starijim i manje zanimljivim“ kemoterapeuticima. Zbog povremene nestašice karmustina, jednog od osnovnih kemoterapeutika
pri kondicioniranju prije autologne transplantacije krvotvornih matičnih stanica (ATK S) u oboljelih od
limfoma, u našem se centru od 2016. godine on zamjenjuje bendamustinom. U ovom radu retrospektivno analiziramo
tijek ATK S-a u 41 bolesnika koji su primili bendamustin u sklopu protokola BeEA M te ga uspoređujemo s tijekom
ATK S-a u 40 bolesnika koji su primili karmustin u sklopu protokola BEA M. Medijan oporavka vrijednosti neutrofila
(> 0,5 × 109/l) u skupini koja je primila bendamustin iznosio je 11 dana, dok je u skupini kondicioniranoj karmustinom
iznosio 10 dana. Medijan oporavka vrijednosti trombocita (> 20 × 109/l) bio je duži kod skupine koja je primala bendamustin
(16 prema 13 dana) te su ti bolesnici bili duže ovisni o transfuzijama eritrocita (7 prema 5 dana). Infektivne
komplikacije nisu bile češće nakon primjene bendamustina, ali smo nakon primjene karmustina imali veću pojavu
mukozitisa II. – III. stupnja (35% prema 12%). Nakon primjene bendamustina zabilježen je jedan slučaj nefrotoksičnosti
i kardiotoksičnosti terapije, dok kod primjene karmustina te komplikacije nisu zabilježene. Pri upotrebi bendamustina
kod kondicioniranja u naših bolesnika u ovom trenutku nije utvrđena znatnija hematološka toksičnost u odnosu
prema karmustinu, ali su prisutni dulji period oporavka vrijednosti trombocita te niža incidencija mukozitisa.

• Language: croatian
• Publication type: Scientific paper - Case study
• Publication status: Published
• Peer review: Peer review
• Publication version: Published version
• Journal title: Liječnički vjesnik
• Numbering: vol. 140, no. 11-12, pp. 303-306
• p-ISSN: 0024-3477
• DOI: https://doi.org/doi:10.26800/LV-140-11-12-40
• URN:NBN: urn:nbn:hr:105:733907
• Publication: 2018
• Document URL: http://doi.org/10.26800/LV-140-11-12-40
• Type of resource: Text
• Access conditions: Open access
• Created on: 2024-03-28 10:19:54